{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Higher+protein&page=2",
    "query": {
      "intervention": "Higher protein",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Higher+protein&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T21:30:39.134Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00674648",
      "title": "Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infections"
      ],
      "interventions": [
        {
          "name": "CMV-Peptide-Specific T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2007-08",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2020-03-11",
      "last_synced_at": "2026-09-25T21:30:39.134Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00674648"
    },
    {
      "nct_id": "NCT03911076",
      "title": "Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ASC-US",
        "ASC-H",
        "LSIL"
      ],
      "interventions": [
        {
          "name": "PVX-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "PapiVax Biotech, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 70 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2019-05-22",
      "completion_date": "2022-06-08",
      "has_results": false,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-09-25T21:30:39.134Z",
      "location_count": 6,
      "location_summary": "Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more",
      "locations": [
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Fairfield",
          "state": "Ohio"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Corpus Christi",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03911076"
    },
    {
      "nct_id": "NCT03984448",
      "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma",
        "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Double-Expressor Lymphoma",
        "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present",
        "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 363,
      "start_date": "2019-10-22",
      "completion_date": "2028-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-09-25T21:30:39.134Z",
      "location_count": 634,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03984448"
    },
    {
      "nct_id": "NCT00313508",
      "title": "Dendritic Cell Vaccination During Lymphoid Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intraocular Melanoma",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "Autologous Dendritic Cells (DC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Autologous Lymphocyte Infusion (ALI)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2006-02",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2014-02-21",
      "last_synced_at": "2026-09-25T21:30:39.134Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00313508"
    },
    {
      "nct_id": "NCT04495010",
      "title": "Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-03-31",
      "completion_date": "2027-10-23",
      "has_results": false,
      "last_update_posted_date": "2021-03-19",
      "last_synced_at": "2026-09-25T21:30:39.134Z",
      "location_count": 23,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04495010"
    },
    {
      "nct_id": "NCT01760226",
      "title": "Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "Post Transplant Lymphoproliferative Disorder",
        "Primary Mediastinal (Thymic) Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "DA-EPOCH-R for DLBCL, PTLD, AND PMBCL",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 4,
      "start_date": "2013-01",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-09-25T21:30:39.134Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01760226"
    },
    {
      "nct_id": "NCT04082468",
      "title": "VALIDATE: Factor VIII Trending for MS Relapse",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Blood sample collection for coagulation profile",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-08-13",
      "completion_date": "2022-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-09-21",
      "last_synced_at": "2026-09-25T21:30:39.134Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04082468"
    },
    {
      "nct_id": "NCT00409682",
      "title": "Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Adalimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 192,
      "start_date": "2007-04",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2011-08-04",
      "last_synced_at": "2026-09-25T21:30:39.134Z",
      "location_count": 26,
      "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 22 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00409682"
    },
    {
      "nct_id": "NCT00136084",
      "title": "Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia, Myelocytic, Acute"
      ],
      "interventions": [
        {
          "name": "Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 238,
      "start_date": "2002-08",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2012-12-05",
      "last_synced_at": "2026-09-25T21:30:39.134Z",
      "location_count": 8,
      "location_summary": "Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00136084"
    },
    {
      "nct_id": "NCT00899847",
      "title": "Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transplantation, Homologous",
        "Transplantation, Autologous",
        "Multiple Myeloma",
        "Blood and Marrow Transplant (BMT)"
      ],
      "interventions": [
        {
          "name": "Autologous peripheral blood stem cells (auto-PBSC) transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Allogeneic peripheral blood stem cells (allo-PBSC) transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Total lymphoid irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Rabbit anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mycophenolate Mofetil 250mg",
          "type": "DRUG"
        },
        {
          "name": "Solumedrol",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2009-05",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-10-20",
      "last_synced_at": "2026-09-25T21:30:39.134Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00899847"
    }
  ]
}